Validation issues for the use of transgenic mouse mutation assays in risk assessment.
Gorelick
N J
NJ
Miami Valley Labs, Procter & Gamble Company, Cincinnati, OH 45253-8707, USA.
D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics; D002273:Carcinogens / Q000494:pharmacology*; D004249:DNA Damage; D029968:Escherichia coli Proteins; D005069:Evaluation Studies as Topic; D056968:Lac Repressors; D051379:Mice; D008822:Mice, Transgenic / Q000235:genetics*; D009152:Mutagenicity Tests / Q000592:standards*; D009153:Mutagens / Q000494:pharmacology; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics; D011237:Predictive Value of Tests; D011993:Recombinant Fusion Proteins / Q000235:genetics; D012097:Repressor Proteins / Q000235:genetics; D015203:Reproducibility of Results; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D019076:Transgenes / Q000187:drug effects; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards; D001616:beta-Galactosidase / Q000235:genetics
D001426:Bacterial Proteins; D002273:Carcinogens; D029968:Escherichia coli Proteins; D056968:Lac Repressors; D009153:Mutagens; D011993:Recombinant Fusion Proteins; D012097:Repressor Proteins; D001616:beta-Galactosidase